Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR)-Reference-Cited by-同舟云学术

Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR)

Published:2012-08 Issue:8 Volume:7 Page:1296-1303
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nakagawa Kazuhiko,Kudoh Shoji,Ohe Yuichiro,Johkoh Takeshi,Ando Masahiko,Yamazaki Naoya,Seki Akihiro,Takemoto Shinya,Fukuoka Masahiro

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

2. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study;Kubota;J Thorac Oncol,2008

3. Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer;Takahashi;Anticancer Res,2010

4. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors;Yamamoto;Cancer Chemother Pharmacol,2008

5. Results of gefitinib prospective investigation;Yoshida;Med Drug J,2005

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis;Respiratory Investigation;2024-05

2. Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective;Current Oncology;2023-08-30

3. Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects;Clinical and Translational Science;2022-09-27

4. Machine learning approaches for predicting the onset time of the adverse drug events in oncology;Machine Learning with Applications;2022-09

5. Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world;Journal of Cancer Research and Clinical Oncology;2022-02-07